Biophytis advances Hong Kong joint venture for BIO101 development in Asia

BPTS•2026-08-26

Trial funding use

The funding is aimed at supporting the SARA-31 multi-regional Phase 3 sarcopenia trial through market authorization in China and the EU.

Royalty and funding terms

The joint venture is expected to pay single-digit royalties on future sales under the licensing agreement.

Asian partners are set to fund an initial USD 3 million tranche, part of commitments of up to USD 20 million, including USD 10 million in year one.

Hong Kong joint venture moves ahead

Biophytis moved to implement a Hong Kong joint venture, Biophytis Biopharmaceutical Holding LTD, created June 2, 2026.

Planned contribution includes BIO101 patents in China, Japan and South Korea, paired with a license deal covering those markets.

Sources

Biophytis advances Hong Kong joint venture for BIO101 development in Asia

Sec

Biophytis advances Hong Kong joint venture for BIO101 development in Asia

Trial funding use

Royalty and funding terms

Hong Kong joint venture moves ahead

Related News

IAMGOLD targets 720,000-820,000 oz attributable gold output in 2026 investor presentation

Comstock signs 6,400-sq-ft office lease with Council for Exceptional Children at The Hartford in Arlington, Va

Deere declares quarterly dividend of $1.62 per share

Sources

Biophytis advances Hong Kong joint venture for BIO101 development in Asia

Victory Capital agrees to buy First Eagle from Genstar for $7 billion

Armstrong installs Ultima Templok ceiling system in Nixon Park Nature Center renovation